SinoMab BioScience Limited (HKG:3681)
Hong Kong · Delayed Price · Currency is HKD 1.360
0.00 (0.00%)
Jul 31, 2026, 4:08 PM HKT
SinoMab BioScience Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 322.71 | 61.9 | 203.66 | 345.71 | 562.98 |
Short-Term Investments | 5.83 | 3.89 | 2.87 | 46.2 | 26.55 |
Trading Asset Securities | 48.71 | 44.98 | 30.99 | 30.48 | - |
Cash & Short-Term Investments | 377.25 | 110.77 | 237.53 | 422.39 | 589.53 |
Cash Growth | 240.57% | -53.36% | -43.77% | -28.35% | -35.66% |
Prepaid Expenses | 1.83 | 8.56 | 3.22 | 12.23 | 6.16 |
Other Current Assets | 10.81 | 66 | 29.44 | 12.47 | - |
Total Current Assets | 389.9 | 185.34 | 270.18 | 447.09 | 595.69 |
Property, Plant & Equipment | 501 | 550.72 | 536.77 | 485.82 | 356.21 |
Long-Term Investments | - | - | - | - | 26.93 |
Other Intangible Assets | 0.35 | 0.94 | 1.84 | 2.6 | 1.92 |
Other Long-Term Assets | 16.86 | 16.11 | 38.99 | 72.84 | 60.91 |
Total Assets | 908.11 | 753.1 | 847.79 | 1,008 | 1,042 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accrued Expenses | 2.28 | 3.07 | 5.93 | 11.36 | 7.85 |
Current Portion of Long-Term Debt | 134.72 | 112.64 | 66.59 | 30.42 | 5 |
Current Portion of Leases | 7.58 | 12.94 | 4.66 | 15.38 | 7.39 |
Current Unearned Revenue | - | - | 0.3 | 0.3 | 1.55 |
Other Current Liabilities | 59.46 | 74.85 | 95.17 | 129.93 | 76.57 |
Total Current Liabilities | 204.04 | 203.5 | 172.65 | 187.39 | 98.36 |
Long-Term Debt | 192.09 | 306.65 | 324.81 | 238.36 | 193.78 |
Long-Term Leases | 4.11 | 50.04 | 54.75 | 73.02 | 69.29 |
Total Liabilities | 400.23 | 560.19 | 552.2 | 498.77 | 361.43 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 2,218 | 1,790 | 1,725 | 1,725 | 1,679 |
Retained Earnings | -1,780 | -1,675 | -1,490 | -1,247 | -962.96 |
Comprehensive Income & Other | 70.03 | 78.19 | 60.6 | 31.48 | -35.94 |
Shareholders' Equity | 507.88 | 192.91 | 295.58 | 509.58 | 680.23 |
Total Liabilities & Equity | 908.11 | 753.1 | 847.79 | 1,008 | 1,042 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 338.49 | 482.27 | 450.81 | 357.18 | 275.46 |
Net Cash (Debt) | 38.76 | -371.5 | -213.28 | 65.2 | 314.07 |
Net Cash Growth | - | - | - | -79.24% | -61.62% |
Net Cash Per Share | 0.03 | -0.35 | -0.21 | 0.07 | 0.32 |
Filing Date Shares Outstanding | 1,387 | 1,092 | 1,035 | 1,035 | 1,006 |
Total Common Shares Outstanding | 1,387 | 1,092 | 1,035 | 1,035 | 1,006 |
Working Capital | 185.86 | -18.16 | 97.54 | 259.7 | 497.32 |
Book Value Per Share | 0.37 | 0.18 | 0.29 | 0.49 | 0.68 |
Tangible Book Value | 507.52 | 191.98 | 293.74 | 506.98 | 678.31 |
Tangible Book Value Per Share | 0.37 | 0.18 | 0.28 | 0.49 | 0.67 |
Machinery | 58.66 | 67.2 | 66.4 | 58.61 | 47.02 |
Construction In Progress | 462.89 | 453.07 | 419.14 | 336.16 | 197.47 |
Leasehold Improvements | 28.35 | 28.48 | 28.37 | 33.42 | 29.81 |